Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
04 2021
Historique:
received: 05 09 2020
revised: 18 11 2020
accepted: 20 11 2020
pubmed: 15 12 2020
medline: 15 12 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

To investigate the association between Ki67 index and programmed death-ligand 1 (PD-L1) expression in muscle-invasive bladder cancer (MIBC) patients after RC. We retrospectively evaluated 262 MIBC patients treated with RC between April 2004 and April 2020. The impact of Ki67 index and PD-L1 expression on prognosis was evaluated by univariate Cox regression analysis. In addition, a pathomolecular risk score, including Ki67 and PD-L1, was developed to predict prognosis and pathological factors. We also evaluated the link between the Ki67 index and PD-L1 under the IL-6 stimulation in the bladder cancer cell lines of T24 and 5637 cells. The median age and follow-up period was 69 years and 52 months, respectively. Ki67 index and PD-L1 expression were significantly associated with tumor recurrence. Univariate Cox regression analysis showed that pT3-4, mixed histology, lymphovascular invasion positive (LVI+), pN+, Ki67-high (>17%), and PD-L1+ were significantly associated with recurrence-free survival (RFS). The pathomolecular risk score was developed using resection margin+ (1 point), mixed histology (1 point), LVI+ (1 point), pN+ (1 point), and Ki67-high (1 point). RFS and overall survival were significantly shorter in patients with higher pathomolecular risk scores (>1) than in those with lower risk scores (≤1). Cell proliferation was significantly increased in the T24 and 5637 cells under the IL-6 stimulation, while PD-L1 expression was not. A significant effect of Ki67-high and PD-L1 expression on poor prognosis was observed in patients with MIBC. Further studies are necessary to elucidate the precise mechanisms of cell proliferation and PD-L1 expression in patients with MIBC.

Identifiants

pubmed: 33308976
pii: S1078-1439(20)30616-5
doi: 10.1016/j.urolonc.2020.11.029
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
Ki-67 Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

238.e9-238.e17

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Hirotaka Horiguchi (H)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Shingo Hatakeyama (S)

Department of Advanced Blood Purification Therapy, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp.

Tohru Yoneyama (T)

Department of Glycotechnology, Center for Advanced Medical Research.

Mihoko Sutoh Yoneyama (MS)

Department of Cancer Immunology and Cell Biology, Oyokyo Kidney Research Institute, Hirosaki, Japan.

Toshikazu Tanaka (T)

Department of Urology, Aomori Prefectural Central Hospital, Japan.

Naoki Fujita (N)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Teppei Okamoto (T)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Hayato Yamamoto (H)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Takahiro Yoneyama (T)

Department of Advanced Transplant and Regenerative Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan.

Tadashi Yoshizawa (T)

Department of Pathology and Bioscience, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan.

Yasuhiro Hashimoto (Y)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Toshiaki Kawaguchi (T)

Department of Urology, Aomori Prefectural Central Hospital, Japan.

Chikara Ohyama (C)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Blood Purification Therapy, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Transplant and Regenerative Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH